Illidge TM - Search Results

1

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J. Dovedi SJ, et al. Among authors: illidge tm. Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30. Cancer Immunol Res. 2016. PMID: 27241845 Free PMC article.

2

Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.

Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, Fearon DT, Parkhouse RM, Klaus GG, Glennie MJ. Tutt AL, et al. Among authors: illidge tm. J Immunol. 1998 Sep 15;161(6):3176-85. J Immunol. 1998. PMID: 9743386

3

The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma.

Illidge TM, Cragg MS, McBride HM, French RR, Glennie MJ. Illidge TM, et al. Blood. 1999 Jul 1;94(1):233-43. Blood. 1999. PMID: 10381518 Free article.

4

A new in vivo and in vitro B cell lymphoma model, pi-BCL1.

Illidge T, Honeychurch J, Howatt W, Ross F, Wilkins B, Cragg M. Illidge T, et al. Cancer Biother Radiopharm. 2000 Dec;15(6):571-80. doi: 10.1089/cbr.2000.15.571. Cancer Biother Radiopharm. 2000. PMID: 11190489

5

Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.

Illidge T, Honeychurch J, Vandersteen A, Cragg M. Illidge T, et al. Cancer Biother Radiopharm. 2000 Dec;15(6):581-91. doi: 10.1089/cbr.2000.15.581. Cancer Biother Radiopharm. 2000. PMID: 11190490

6

Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.

Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Honeychurch J, et al. Among authors: illidge tm. Blood. 2003 Aug 15;102(4):1449-57. doi: 10.1182/blood-2002-12-3717. Epub 2003 Apr 24. Blood. 2003. PMID: 12714523 Free article.

7

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy.

Du Y, Honeychurch J, Cragg MS, Bayne M, Glennie MJ, Johnson PW, Illidge TM. Du Y, et al. Among authors: illidge tm. Blood. 2004 Feb 15;103(4):1485-94. doi: 10.1182/blood-2003-06-2037. Epub 2003 Oct 23. Blood. 2004. PMID: 14576070 Free article.

8

Apparent modulation of CD20 by rituximab: an alternative explanation.

Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Cragg MS, et al. Among authors: illidge tm. Blood. 2004 May 15;103(10):3989-90; author reply 3990-1. doi: 10.1182/blood-2003-12-4384. Blood. 2004. PMID: 15121717 Free article. No abstract available.

9

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.

Cragg MS, Bayne MB, Tutt AL, French RR, Beers S, Glennie MJ, Illidge TM. Cragg MS, et al. Among authors: illidge tm. Blood. 2004 Oct 15;104(8):2540-2. doi: 10.1182/blood-2004-05-1733. Epub 2004 Jun 22. Blood. 2004. PMID: 15213098 Free article.

10

Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.

Honeychurch J, Glennie MJ, Illidge TM. Honeychurch J, et al. Among authors: illidge tm. Cancer Res. 2005 Aug 15;65(16):7493-501. doi: 10.1158/0008-5472.CAN-04-3808. Cancer Res. 2005. PMID: 16103104

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page